Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Enfortumab Vedotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PADCEV (DIN 02521903) under ATC L01FX13 ENFORTUMAB VEDOTIN. Indications are not published in the Drug Product… | DIN02521903 | approvedsource: Marketed | health-canada-dpd |
| Dec 16, 2021 | Brexucabtagene Autoleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECARTUS (DIN 02516667) under ATC L01XL06 BREXUCABTAGENE AUTOLEUCEL. Indications are not published in the Drug… | DIN02516667 | approvedsource: Marketed | health-canada-dpd |
| Dec 6, 2021 | Lurbinectedin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZEPZELCA (DIN 02520834) under ATC L01XX69 LURBINECTEDIN. Indications are not published in the Drug Product Database —… | DIN02520834 | withdrawnsource: Dormantsince Jun 17, 2026 | health-canada-dpd |
| Dec 6, 2021 | Tafasitamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as MINJUVI (DIN 02518627) under ATC L01FX12 TAFASITAMAB. Indications are not published in the Drug Product Database —… | DIN02518627 | approvedsource: Marketed | health-canada-dpd |
| Dec 2, 2021 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 02473763) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02473763 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 30, 2021 | Pemigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMAZYRE (DIN 02519941) under ATC L01EN02 PEMIGATINIB. Indications are not published in the Drug Product Database —… | DIN02519941 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Polatuzumab Vedotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as POLIVY (DIN 02515431) under ATC L01FX14 POLATUZUMAB VEDOTIN. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514796) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2021 | Treosulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRECONDYV (DIN 02517388) under ATC L01AB02 TREOSULFAN. Indications are not published in the Drug Product Database —… | DIN02517388 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 20, 2021 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MINT-LETROZOLE (DIN 02508109) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02508109 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 25, 2021 | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE INJECTION, USP (DIN 02511347) under ATC L01CA04 VINORELBINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 28, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02498103) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 27, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP IMATINIB (DIN 02495074) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02495074 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 26, 2021 | Pemigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMAZYRE (DIN 02519968) under ATC L01EN02 PEMIGATINIB. Indications are not published in the Drug Product Database —… | DIN02519968 | approvedsource: Marketed | health-canada-dpd |
| Nov 22, 2021 | Sacituzumab Govitecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRODELVY (DIN 02520788) under ATC L01FX17 SACITUZUMAB GOVITECAN. Indications are not published in the Drug Product… | DIN02520788 | approvedsource: Marketed | health-canada-dpd |
| Nov 12, 2021 | Pralsetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GAVRETO (DIN 02517590) under ATC L01EX23 PRALSETINIB. Indications are not published in the Drug Product Database —… | DIN02517590 | withdrawnsource: Cancelled Post Marketsince Feb 26, 2025 | health-canada-dpd |
| Nov 9, 2021 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BAMBEVI (DIN 02520737) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02520737 | approvedsource: Marketed | health-canada-dpd |
| Nov 9, 2021 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BAMBEVI (DIN 02520729) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02520729 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 22, 2021 | Sotorasib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUMAKRAS (DIN 02520095) under ATC L01XX73 SOTORASIB. Indications are not published in the Drug Product Database — see… | DIN02520095 | approvedsource: Marketed | health-canada-dpd |
| Oct 22, 2021 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02514990) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02514990 | approvedsource: Marketed | health-canada-dpd |
| Oct 22, 2021 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02514982) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02514982 | approvedsource: Marketed | health-canada-dpd |
| Oct 21, 2021 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-METHOTREXATE (DIN 02509067) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02509067 | approvedsource: Marketed | health-canada-dpd |
| Oct 7, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as KANJINTI (DIN 02518244) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02518244 | approvedsource: Marketed | health-canada-dpd |
| Oct 7, 2021 | Tepotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEPMETKO (DIN 02516322) under ATC L01EP02 TEPOTINIB. Indications are not published in the Drug Product Database — see… | DIN02516322 | approvedsource: Marketed | health-canada-dpd |
| Oct 5, 2021 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as MINT-CAPECITABINE (DIN 02508028) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02508028 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514788) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514788 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514761) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514761 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514753) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514753 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514745) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514745 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514737) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514737 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 30, 2021 | Bacillus Calmette-Guérin (bcg) - Strain Russian Bcg-I | Health Canada CA | cancer not stated in this record | Marketed in Canada as VERITY-BCG (DIN 02508613) under ATC L03AX03 BCG VACCINE. Indications are not published in the Drug Product Database —… | DIN02508613 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 6, 2021 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VYXEOS (DIN 02515490) under ATC L01XY01 CYTARABINE AND DAUNORUBICIN. Indications are not published in the Drug… | DIN02515490 | approvedsource: Marketed | health-canada-dpd |
| Jul 6, 2021 | Daunorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as VYXEOS (DIN 02515490) under ATC L01XY01 CYTARABINE AND DAUNORUBICIN. Indications are not published in the Drug… | DIN02515490 | approvedsource: Marketed | health-canada-dpd |
| Jul 5, 2021 | Encorafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BRAFTOVI (DIN 02513099) under ATC L01EC03 ENCORAFENIB. Indications are not published in the Drug Product Database —… | DIN02513099 | approvedsource: Marketed | health-canada-dpd |
| Jul 5, 2021 | Binimetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEKTOVI (DIN 02513080) under ATC L01EE03 BINIMETINIB. Indications are not published in the Drug Product Database —… | DIN02513080 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Sep 25, 2025 |
| health-canada-dpd |
| May 20, 2021 | Fedratinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as INREBIC (DIN 02502445) under ATC L01EJ02 FEDRATINIB. Indications are not published in the Drug Product Database — see… | DIN02502445 | approvedsource: Marketed | health-canada-dpd |
| May 7, 2021 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-PEMETREXED (DIN 02480492) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product… | DIN02480492 | approvedsource: Marketed | health-canada-dpd |
| May 6, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02509172) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02509172 | withdrawnsource: Dormantsince Jul 31, 2023 | health-canada-dpd |
| May 6, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02509164) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02509164 | withdrawnsource: Dormantsince Jul 31, 2024 | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478358) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478358 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478331) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478331 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478323) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478323 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478315) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478315 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478307) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478307 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Jul 31, 2025 |
| health-canada-dpd |
| Apr 27, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP IMATINIB (DIN 02495066) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02495066 | withdrawnsource: Dormantsince Jul 31, 2025 | health-canada-dpd |
| Apr 21, 2021 | Rituximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIABNI (DIN 02513447) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02513447 | withdrawnsource: Cancelled Post Marketsince Oct 10, 2024 | health-canada-dpd |
| Apr 12, 2021 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-BORTEZOMIB (DIN 02499061) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02499061 | approvedsource: Marketed | health-canada-dpd |
| Apr 9, 2021 | Pertuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512920) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512920 | approvedsource: Marketed | health-canada-dpd |
| Apr 9, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512920) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512920 | approvedsource: Marketed | health-canada-dpd |
| Apr 8, 2021 | Pertuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512912) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512912 | approvedsource: Marketed | health-canada-dpd |